Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04002297




Registration number
NCT04002297
Ethics application status
Date submitted
27/06/2019
Date registered
28/06/2019
Date last updated
29/10/2024

Titles & IDs
Public title
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
Scientific title
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Secondary ID [1] 0 0
2019-000413-36
Secondary ID [2] 0 0
BGB-3111-306
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - zanubrutinib
Treatment: Drugs - bendamustine
Treatment: Drugs - rituximab

Experimental: zanubrutinib plus rituximab -

Active comparator: bendamustine plus rituximab -


Treatment: Drugs: zanubrutinib
Administered as two 80 mg capsules by mouth twice a day

Treatment: Drugs: bendamustine
Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

Treatment: Drugs: rituximab
Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS) determined by independent central review
Timepoint [1] 0 0
Up to 7 years
Secondary outcome [1] 0 0
PFS by investigator
Timepoint [1] 0 0
Up to 7 years
Secondary outcome [2] 0 0
Overall response rate (ORR)
Timepoint [2] 0 0
Up to 7 years
Secondary outcome [3] 0 0
Duration of response (DOR)
Timepoint [3] 0 0
Up to 7 years
Secondary outcome [4] 0 0
Overall survival (OS)
Timepoint [4] 0 0
Up to 7 years
Secondary outcome [5] 0 0
Participant-reported outcomes (PROs) as assessed by the EQ-5D-5L questionnaire
Timepoint [5] 0 0
Up to 7 years
Secondary outcome [6] 0 0
PROs as assessed by the EORTC QLQ-C30 questionnaire
Timepoint [6] 0 0
Up to 7 years
Secondary outcome [7] 0 0
Occurrence and severity of treatment-emergent adverse events (safety and tolerability)
Timepoint [7] 0 0
Up to 7 years

Eligibility
Key inclusion criteria
Key

1. =70 years of age at the time of informed consent, OR =60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
2. Histologically confirmed diagnosis of MCL
3. No prior systemic treatments for MCL
4. Measurable disease by CT/MRI
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
6. Adequate marrow and organ function

Key
Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known central nervous system involvement by lymphoma
2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
3. Clinically significant cardiovascular disease
4. History of severe bleeding disorder
5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
6. Active fungal, bacterial and/or viral infection requiring systemic therapy
7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/08/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
Accrual to date
Final
510
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Canberra Hospital - Garran
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
The Tweed Valley Hospital - Cudgen
Recruitment hospital [4] 0 0
Saint Vincents Hospital Sydney - Darlinghurst
Recruitment hospital [5] 0 0
Gosford Hospital - Gosford
Recruitment hospital [6] 0 0
Sunshine Coast Hospital and Health Service - Birtinya
Recruitment hospital [7] 0 0
Flinders Medical Centre - Bedford PK
Recruitment hospital [8] 0 0
Monash Health - Clayton
Recruitment hospital [9] 0 0
St Vincents Hospital Melbourne - Fitzroy
Recruitment hospital [10] 0 0
Peninsula Private Hospital - Frankston
Recruitment hospital [11] 0 0
Barwon Health the Geelong Hospital - Geelong
Recruitment hospital [12] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2487 - Cudgen
Recruitment postcode(s) [4] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [5] 0 0
2250 - Gosford
Recruitment postcode(s) [6] 0 0
4575 - Birtinya
Recruitment postcode(s) [7] 0 0
5042 - Bedford PK
Recruitment postcode(s) [8] 0 0
3168 - Clayton
Recruitment postcode(s) [9] 0 0
3065 - Fitzroy
Recruitment postcode(s) [10] 0 0
3199 - Frankston
Recruitment postcode(s) [11] 0 0
3220 - Geelong
Recruitment postcode(s) [12] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Nevada
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Oregon
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Austria
State/province [11] 0 0
Linz
Country [12] 0 0
Austria
State/province [12] 0 0
Salzburg
Country [13] 0 0
Austria
State/province [13] 0 0
Vienna
Country [14] 0 0
Belgium
State/province [14] 0 0
Brugge
Country [15] 0 0
Belgium
State/province [15] 0 0
Brussels
Country [16] 0 0
Belgium
State/province [16] 0 0
Edegem
Country [17] 0 0
Belgium
State/province [17] 0 0
Kortrijk
Country [18] 0 0
Belgium
State/province [18] 0 0
Liege
Country [19] 0 0
Belgium
State/province [19] 0 0
Yvoir
Country [20] 0 0
Canada
State/province [20] 0 0
Ontario
Country [21] 0 0
Canada
State/province [21] 0 0
Quebec
Country [22] 0 0
China
State/province [22] 0 0
Beijing
Country [23] 0 0
China
State/province [23] 0 0
Fujian
Country [24] 0 0
China
State/province [24] 0 0
Guangdong
Country [25] 0 0
China
State/province [25] 0 0
Heilongjiang
Country [26] 0 0
China
State/province [26] 0 0
Henan
Country [27] 0 0
China
State/province [27] 0 0
Hunan
Country [28] 0 0
China
State/province [28] 0 0
Jiangsu
Country [29] 0 0
China
State/province [29] 0 0
Jiangxi
Country [30] 0 0
China
State/province [30] 0 0
Jilin
Country [31] 0 0
China
State/province [31] 0 0
Liaoning
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Sichuan
Country [34] 0 0
China
State/province [34] 0 0
Tianjin
Country [35] 0 0
China
State/province [35] 0 0
Xinjiang
Country [36] 0 0
China
State/province [36] 0 0
Zhejiang
Country [37] 0 0
France
State/province [37] 0 0
Bordeaux
Country [38] 0 0
France
State/province [38] 0 0
Brest
Country [39] 0 0
France
State/province [39] 0 0
Dijon
Country [40] 0 0
France
State/province [40] 0 0
Grenoble Cedex
Country [41] 0 0
France
State/province [41] 0 0
Le Mans
Country [42] 0 0
France
State/province [42] 0 0
Lille
Country [43] 0 0
France
State/province [43] 0 0
Marseille
Country [44] 0 0
France
State/province [44] 0 0
Nantes Cedex
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
France
State/province [46] 0 0
PierreBenite
Country [47] 0 0
France
State/province [47] 0 0
Poitiers
Country [48] 0 0
France
State/province [48] 0 0
Quimper
Country [49] 0 0
France
State/province [49] 0 0
Toulouse
Country [50] 0 0
Germany
State/province [50] 0 0
Heidelberg
Country [51] 0 0
Germany
State/province [51] 0 0
Koln
Country [52] 0 0
Germany
State/province [52] 0 0
Munich
Country [53] 0 0
Germany
State/province [53] 0 0
Ulm
Country [54] 0 0
Germany
State/province [54] 0 0
Wuppertal
Country [55] 0 0
Ireland
State/province [55] 0 0
Cork
Country [56] 0 0
Ireland
State/province [56] 0 0
Dublin
Country [57] 0 0
Ireland
State/province [57] 0 0
Galway
Country [58] 0 0
Ireland
State/province [58] 0 0
Limerick
Country [59] 0 0
Ireland
State/province [59] 0 0
Waterford
Country [60] 0 0
Italy
State/province [60] 0 0
Alessandria
Country [61] 0 0
Italy
State/province [61] 0 0
Bologna
Country [62] 0 0
Italy
State/province [62] 0 0
Genova
Country [63] 0 0
Italy
State/province [63] 0 0
Milano
Country [64] 0 0
Italy
State/province [64] 0 0
Novara
Country [65] 0 0
Italy
State/province [65] 0 0
Palermo
Country [66] 0 0
Italy
State/province [66] 0 0
Pisa
Country [67] 0 0
Italy
State/province [67] 0 0
Ravenna
Country [68] 0 0
Italy
State/province [68] 0 0
Reggio Emilia
Country [69] 0 0
Italy
State/province [69] 0 0
Roma
Country [70] 0 0
Italy
State/province [70] 0 0
Siena
Country [71] 0 0
Italy
State/province [71] 0 0
Torino
Country [72] 0 0
Italy
State/province [72] 0 0
Verona
Country [73] 0 0
Japan
State/province [73] 0 0
Chiba
Country [74] 0 0
Japan
State/province [74] 0 0
Hiroshima
Country [75] 0 0
Japan
State/province [75] 0 0
Kanagawa
Country [76] 0 0
Japan
State/province [76] 0 0
Miyagi
Country [77] 0 0
Japan
State/province [77] 0 0
Okayama
Country [78] 0 0
Japan
State/province [78] 0 0
Osaka
Country [79] 0 0
Japan
State/province [79] 0 0
Tokyo
Country [80] 0 0
Japan
State/province [80] 0 0
Yokohamashi
Country [81] 0 0
Netherlands
State/province [81] 0 0
Den Haag
Country [82] 0 0
Netherlands
State/province [82] 0 0
Goes
Country [83] 0 0
Netherlands
State/province [83] 0 0
Groningen
Country [84] 0 0
Netherlands
State/province [84] 0 0
Nieuwegein
Country [85] 0 0
Netherlands
State/province [85] 0 0
Nijmegen
Country [86] 0 0
Netherlands
State/province [86] 0 0
Rotterdam
Country [87] 0 0
New Zealand
State/province [87] 0 0
Christchurch
Country [88] 0 0
New Zealand
State/province [88] 0 0
Tauranga
Country [89] 0 0
Poland
State/province [89] 0 0
Bydgoszcz
Country [90] 0 0
Poland
State/province [90] 0 0
Chorzow
Country [91] 0 0
Poland
State/province [91] 0 0
Gdansk
Country [92] 0 0
Poland
State/province [92] 0 0
Gdask
Country [93] 0 0
Poland
State/province [93] 0 0
Gdynia
Country [94] 0 0
Poland
State/province [94] 0 0
Krakow
Country [95] 0 0
Poland
State/province [95] 0 0
Legnica
Country [96] 0 0
Poland
State/province [96] 0 0
Lodz
Country [97] 0 0
Poland
State/province [97] 0 0
Lublin
Country [98] 0 0
Poland
State/province [98] 0 0
Walbrzych
Country [99] 0 0
Poland
State/province [99] 0 0
Warszawa
Country [100] 0 0
Poland
State/province [100] 0 0
Wroclaw
Country [101] 0 0
Portugal
State/province [101] 0 0
Lisboa
Country [102] 0 0
Portugal
State/province [102] 0 0
Lisbon
Country [103] 0 0
Portugal
State/province [103] 0 0
Porto
Country [104] 0 0
Romania
State/province [104] 0 0
Bucuresti
Country [105] 0 0
Romania
State/province [105] 0 0
Iasi
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Moskva
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Sankt-Peterburg
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Moscow
Country [109] 0 0
Spain
State/province [109] 0 0
Barcelona
Country [110] 0 0
Spain
State/province [110] 0 0
Girona
Country [111] 0 0
Spain
State/province [111] 0 0
Madrid
Country [112] 0 0
Spain
State/province [112] 0 0
Malaga
Country [113] 0 0
Spain
State/province [113] 0 0
Sevilla
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taipei
Country [115] 0 0
Turkey
State/province [115] 0 0
Ankara
Country [116] 0 0
Turkey
State/province [116] 0 0
Edirne
Country [117] 0 0
Turkey
State/province [117] 0 0
Istanbul
Country [118] 0 0
Turkey
State/province [118] 0 0
Mersin
Country [119] 0 0
Ukraine
State/province [119] 0 0
Cherkasy
Country [120] 0 0
Ukraine
State/province [120] 0 0
Dnipro
Country [121] 0 0
Ukraine
State/province [121] 0 0
Kiev
Country [122] 0 0
Ukraine
State/province [122] 0 0
Lviv
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Abergavenny
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Birmingham
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Dudley
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Trial website
https://clinicaltrials.gov/study/NCT04002297
Trial related presentations / publications
Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BeiGene
Address 0 0
Country 0 0
Phone 0 0
1-877-828-5568
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04002297